Seattle-based Adaptive Biotechnologies Corp. won de novo clearance for its Clonoseq Assay to detect and monitor minimal residual disease (MRD) in patients with multiple myeloma (MM) and B-cell acute lymphoblastic leukemia (ALL) using DNA from bone marrow samples. Read More
